Julie Anne Smith


Julie Anne Smith currently serves as Chief Executive Officer (CEO) and member of the Board of Directors of Nuvig Therapeutics, a biopharma company developing proprietary recombinant human therapeutics for patients with autoimmune diseases.

Ms. Smith has over 20 years of experience in the life science industry, with a focus on leading private and public biotech companies through development and commercialization of therapeutics for orphan diseases. She served as President and CEO of ESCAPE Bio, a biotech company developing precisely targeted therapies for genetic forms of neurodegeneration. She previously served as President and CEO of Raptor Pharmaceuticals, a commercial stage company until its acquisition by Horizon Pharmaceuticals. Ms. Smith also served as Chief Commercial Officer of Enobia Pharmaceuticals until it was acquired by Alexion Pharmaceuticals.

Earlier in her career, she held roles at Jazz Pharmaceuticals, Genzyme, Novazyme, and Bristol-Myers Squibb. Ms. Smith previously served on the board of directors of Audentes Therapeutics, Inc., a genetic medicines company, and as a director on the Health and Emerging Companies Section Governing Boards of the Biotechnology Industry Organization (BIO). She currently serves on the board of directors of Exelixis, Inc., a public genomics-based drug discovery company. Ms. Smith holds a B.S. in biological and nutritional sciences from Cornell University.